Ivabradine
Ivabradine Ranbaxy (ivabradine) is used to treat heart conditions:
Stable angina pectoris (usually called angina)
This is a heart condition that occurs when the heart muscle does not receive enough oxygen. This condition usually occurs in people between 40 and 50 years old. The most common symptom is pain or discomfort in the chest. Angina occurs more frequently with increased heart activity, for example, during exercise, under the influence of emotions, cold, or after a meal. In people with angina, increased heart activity can cause chest pain.
Chronic heart failure
This condition occurs when the heart cannot pump enough blood to the body. The most common symptoms are shortness of breath, fatigue, tiredness, and swelling of the ankles.
How does Ivabradine Ranbaxy work?
The medicine works mainly by slowing down the heart rate by a few beats per minute. This leads to a reduction in the heart muscle's demand for oxygen, especially in situations where angina pain is more likely to occur. In this way, the medicine helps control and reduce the frequency of angina attacks.
Additionally, since increased heart activity has an adverse effect on heart function and survival in patients with chronic heart failure, the specific action of ivabradine, which reduces heart rate, helps improve heart function and survival.
If any of the above conditions apply to the patient (before or during treatment with Ivabradine Ranbaxy), they should consult their doctor immediately.
Before starting to take Ivabradine Ranbaxy, the patient should discuss it with their doctor or pharmacist:
If any of the above conditions apply to the patient (before or during treatment with Ivabradine Ranbaxy), they should consult their doctor immediately.
Ivabradine Ranbaxy is not intended for use in children and adolescents under 18 years of age.
The patient should tell their doctor or pharmacist about all medicines they are taking, have recently taken, or plan to take.
The patient should not drink grapefruit juice while taking this medicine.
The patient should not take this medicine if they are pregnant or plan to become pregnant (see "When not to take Ivabradine Ranbaxy").
The patient should consult their doctor if they become pregnant while taking Ivabradine Ranbaxy.
A woman of childbearing age should not take this medicine unless they use effective methods of contraception (see "When not to take Ivabradine Ranbaxy").
The patient should not take this medicine while breastfeeding (see "When not to take Ivabradine Ranbaxy"). The patient should consult their doctor if they are breastfeeding or plan to breastfeed, as breastfeeding should be stopped if the patient takes Ivabradine Ranbaxy.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should ask their doctor or pharmacist for advice before taking this medicine.
This medicine may cause temporary vision disturbances (transient sensations of seeing strong light, see "Possible side effects"). If this occurs, the patient should be cautious while driving or operating machinery, especially in situations where there may be sudden changes in lighting, especially when driving at night.
Ivabradine Ranbaxy contains sunset yellow FCF, which may cause allergic reactions.
The medicine contains less than 1 mmol (23 mg) of sodium per 5 mg or 7.5 mg film-coated tablet, which means it is essentially "sodium-free".
The patient should always take this medicine exactly as their doctor or pharmacist has told them. If they are not sure, they should ask their doctor or pharmacist.
Ivabradine Ranbaxy should be taken with food.
Treatment of stable angina pectoris
The initial dose should not be more than one 5 mg tablet twice a day. If symptoms of angina pectoris persist and the 5 mg twice daily dose is well tolerated, the doctor may recommend increasing the dose. The maintenance dose should not exceed 7.5 mg twice a day. The doctor will determine the appropriate dose for the patient. The usual dose is one tablet in the morning and one in the evening. In some cases (e.g., in elderly patients), the doctor may recommend half the dose, i.e., half a 5 mg tablet (equivalent to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
Treatment of chronic heart failure
The recommended initial dose is one 5 mg tablet twice a day; if necessary, the dose can be increased to one 7.5 mg tablet twice a day. The doctor will determine the dose suitable for the patient. The usual dose is one tablet in the morning and one in the evening. In some cases (e.g., in elderly patients), the doctor may recommend half the dose, i.e., half a 5 mg tablet (equivalent to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
If the patient takes too much of the medicine, they may experience shortness of breath or fatigue, as the heart rate slows down too much. In this case, they should consult their doctor immediately.
If the patient misses a dose of Ivabradine Ranbaxy, they should take the next dose at the usual time. They should not take a double dose to make up for the forgotten dose.
The days of the week printed on the blister pack will help them remember when they last took the medicine.
Because the treatment of angina pectoris or chronic heart failure is usually long-term, the patient should consult their doctor before stopping this medicine.
If the patient feels that the effect of the medicine is too strong or too weak, they should consult their doctor or pharmacist.
If the patient has any further questions on the use of this medicine, they should ask their doctor or pharmacist.
Like all medicines, Ivabradine Ranbaxy can cause side effects, although not everybody gets them.
The most common side effects of this medicine are dose-dependent and related to its mechanism of action:
Very common(may affect more than 1 in 10 people)
Visual disturbances (transient sensations of seeing strong light, usually caused by sudden changes in lighting). These disturbances are also described as auras, colorful flashes, split images, or multiple images. They usually occur within the first two months of treatment and may recur several times and resolve during or after treatment.
Common(may affect up to 1 in 10 people)
Heart rate disorders (slow heart rate), which occur especially within the first 2 to 3 months of treatment.
Other side effects have also been reported:
Common(may affect up to 1 in 10 people)
Rapid, irregular heartbeats, palpitations, uncontrolled blood pressure, headache, dizziness, and blurred vision.
Uncommon(may affect up to 1 in 100 people)
Palpitations and extra beats, nausea, constipation, diarrhea, abdominal pain, feeling of spinning (vertigo), breathing difficulties (dyspnea), muscle cramps, and changes in laboratory parameters: high uric acid levels in the blood, increased eosinophil count in the blood (a type of white blood cell), and increased creatinine levels in the blood (a muscle breakdown product), rash, angioedema (e.g., facial, tongue, or throat swelling, difficulty breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of weakness, abnormal ECG, double vision, worsening vision.
Rare(may affect up to 1 in 1,000 people)
Hives, itching, skin redness, malaise.
Very rare(may affect up to 1 in 10,000 people)
Irregular heartbeat.
Reporting side effects
If the patient experiences any side effects, including those not listed in the leaflet, they should tell their doctor or pharmacist, or nurse.
Side effects can be reported directly to the
Department of Pharmacovigilance
National Institute of Pharmacy and Medicines
Al. Jerozolimskie 181C, 02-222 Warsaw
tel.: 22 49-21-301, fax: 22 49-21-309,
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, more information can be gathered on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date (EXP) stated on the carton and blister.
The expiry date refers to the last day of the month.
The batch number is defined as Lot.
There are no special precautions for storage.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.
Ivabradine Ranbaxy 5 mg: the tablets are salmon-colored, oblong, film-coated, with a score line to facilitate breaking the tablet on both sides, with the marking "5" on one side and smooth on the other. The approximate size is 8.6 mm x 4.5 mm.
The tablet can be divided into equal doses.
Ivabradine Ranbaxy 7.5 mg: the tablets are salmon-colored, triangular, film-coated, with the marking "7.5" on one side and smooth on the other. The approximate size is 7.6 mm x 7.1 mm.
The tablets are in aluminum/OPA/aluminum/PVC blisters with the days of the week printed on them. The cardboard boxes contain 56 or 112 tablets.
Not all pack sizes may be marketed.
Ranbaxy (Poland) Sp. z o.o.
ul. Idzikowskiego 16
00-710 Warsaw
Remedica Ltd
Aharnon Street, Limassol Industrial Estate
3056 Limassol, Cyprus
Date of last revision of the leaflet: 02.05.2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.